New data accepted for publication show Galvus 50 mg twice-daily dose as effective as a thiazolidinedione (TZD), well tolerated and not causing weight gain Novartis proposes improving Galvus ...
Novartis said Monday that the FDA has requested additional data on the drugmaker’s experimental diabetes treatment Galvus, potentially delaying launch of the drug for up to a year and helping Merck’s ...
- Both Eucreas and Galvus to be available to patients in the first EU countries in the next few weeks Basel, February 25, 2008 - European health authorities have approved Eucreas®, an oral tablet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results